Kanghong Pharmaceutical Co., Ltd. (002773.SZ) obtained the registration certificate for Brivaracetam tablets.

Intelligen Finance APP News, Kanghong Pharmaceutical (002773.SZ) announced that the company recently received the "Drug Registration Certificate" for brivaracetam tablets issued by the National Medical Products Administration (Certificate No.: 2025S03922, 2025S03923), and it has been approved for registration. The mechanism of action of brivaracetam in the treatment of schizophrenia is not yet clear, but it may be mediated by partial agonist activity of 5-hydroxytryptamine 5-HT1A and dopamine D2 receptors, as well as antagonist activity of 5-hydroxytryptamine 5-HT2A receptors.